Clinical trial
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
NCT00629525
Study timeline
Study start (unknown)2005-08-01Date precision: month
Registry last updated2015-03-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Hormone Refractory Prostate Cancerunresolved
Interventions
RAD001DRUG
Sponsors & collaborators
Daniel George, MDlead sponsor
Novartis Pharmaceuticalscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00629525 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.